Skip to main content
NewslettersWatchlist

Pharmacielo Ltd(PCLO-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.090
Day High0.090
Open:0.090
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
PharmaCielo Announces Intention to Extend Expiry Date of Warrants
Newsfile
PharmaCielo Announces Change to Financial Year-End, and Appointment of Davidson & Company LLP as Auditor Effective October 7, 2024
Newsfile
PharmaCielo Announces Financial Results for the Second Quarter Ended June 30, 2024
Newsfile
CORRECTION FROM SOURCE: PharmaCielo Provides Update on Reinstatement for Trading
Newsfile
PharmaCielo Provides Update on Reinstatement for Trading
Newsfile
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023, and the First Quarter Ended March 31, 2024
Newsfile
PharmaCielo Announces Issuance of Failure to File Cease Trade Order
Newsfile
PharmaCielo Signs Binding Letter of Intent to Acquire Operations in Thailand; Announces $2 Million Non-Brokered Private Placement with Participation from PharmaCielo Insiders and Siam Ventures Investors
Newsfile
PharmaCielo to Supply Ease Labs with Commercial Shipments of API to Fulfill Contract with State Government of Sao Paulo, Brazil
Newsfile
Colombian Government Continues its Support of Domestic Cannabis Industry - Resolution Extending THC Inventory Allowance Provides Immediate Benefit to PharmaCielo
Newsfile
Benuvia and PharmaCielo Announce Strategic Partnership to Manufacture cGMP Pharmaceutical-Grade CBD Isolate and Related Products
Newsfile
PharmaCielo Announces Q3 2023 Financial Results
Newsfile
PharmaCielo Raises $3.3 Million Under Previously Announced Non-Brokered Private Placement
Newsfile
PharmaCielo Announces Q2 2023 Financial Results
Newsfile
PharmaCielo Provides Corporate Update
Newsfile
PharmaCielo Announces Appointment of Marc Lustig as Chairman and CEO
Newsfile
PharmaCielo Provides Corporate Update
Newsfile
PharmaCielo Announces Q1 2023 Financial Results
Newsfile
PharmaCielo Announces Shipment of Pharmaceutical Grade Cannabis Extract to Customer in South Africa
Newsfile
PharmaCielo Announces Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2022
Newsfile
PharmaCielo Announces Strategic Partnership with CANNPRISMA to Supply EU-GMP Certified Dried Flower to the European Medicinal Cannabis Market
Newswire.ca
PharmaCielo Receives Purchase Order for API from Brazilian Pharmaceutical Company - Represents Third Customer in the Country

Profile

PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico. It generates the majority of its revenue in the form of the Sale of Cannabis derivative products in Colombia.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.